Cancer Genomics Consortium (CGC) Annual Meeting 2026
)
Overview
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. Sequence short to ultra-long DNA/RNA fragments, for a streamlined and rapid solution to comprehensively characterise cancer and tumour research samples: from SNVs to epigenetic alterations and large-scale structural aberrations.
We're looking forward to CGC 2026. Visit Oxford Nanopore at booth #22 to speak to our experts about your application or register for our Platinum Exhibitor Showcase on Monday, August 3 at 1:00pm.
Our Platinum Exhibitor Showcase
From innovation to global impact: adaptive whole genome sequencing for childhood leukemia
Comprehensive genomic profiling is transforming leukemia diagnostics but often requires multiple sequential assays to detect the full spectrum of clinically relevant alterations. In this multicenter global study, an adaptive whole-genome sequencing approach accurately classified leukemia subtypes and identified structural variants, sequence variants, and pharmacogenomic markers with concordance to standard-of-care testing while providing additional molecular characterization in previously unresolved cases. These findings demonstrate the potential of a single comprehensive assay to streamline leukemia genomic testing, improve diagnostic resolution, and support precision oncology in diverse clinical laboratory settings.
Date: Monday, August 3
Time: 1:00 pm-1:15 pm CT
Space is limited so be sure to register in advance.
Please contact events@nanoporetech.com with any questions.
Thomas Alexander, MD, MPH
)
- Job title
- Healthcare professional
- Institution
- University of North Carolina
- Biography
Thomas Alexander, MD, MPH, is combining cancer genomic sequencing with global health research collaborators to increase access to accurate and accessible diagnostic testing for children with cancer.
His priority area of translational research is the development of resource-appropriate diagnostic techniques for pediatric cancer in low- and middle-income countries (LMIC). Over 80% of children who develop cancer worldwide are diagnosed in LMIC, where access to diagnostic technologies is limited, and survival rates are low. To address this health disparity, he is advancing an innovative, cost-effective sequencing approach to expand global access to comprehensive pediatric cancer diagnostics. Dr. Alexander and his collaborators began with a focus on leukemia but have expanded their focus to include pediatric solid tumors. The components of the research include technical and computational development using a Nanopore sequencing approach and an implementation science approach through international collaborations. The research involves close collaborations with researchers in the Department of Biology, the Department of Genetics, and the School of Pharmacy at UNC. Through this research, he collaborates closely with researchers at St. Jude Children’s Research Hospital and with teams in the Netherlands, Malawi, Pakistan, India, Brazil, and Uganda.
